Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
18.33
+0.40 (2.23%)
Nov 21, 2024, 12:39 PM EST - Market open
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for TRDA stock have an average target of 23.33, with a low estimate of 20 and a high estimate of 28. The average target predicts an increase of 27.28% from the current stock price of 18.33.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TRDA stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +52.76% | Nov 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $20 | Strong Buy | Maintains | $18 → $20 | +9.11% | Nov 6, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $25 | Buy | Reiterates | $25 | +36.39% | Aug 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | -1.80% | Aug 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $18 | Strong Buy | Maintains | $20 → $18 | -1.80% | Jun 25, 2024 |
Financial Forecast
Revenue This Year
190.46M
from 129.01M
Increased by 47.63%
Revenue Next Year
48.84M
from 190.46M
Decreased by -74.36%
EPS This Year
0.95
from -0.20
EPS Next Year
-3.22
from 0.95
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 199.4M | 63.0M | 78.8M | ||
| Avg | 190.5M | 48.8M | 65.1M | ||
| Low | 181.3M | 34.3M | 55.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 54.5% | -66.9% | 61.2% | ||
| Avg | 47.6% | -74.4% | 33.3% | ||
| Low | 40.5% | -82.0% | 13.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.25 | -2.28 | -2.03 | ||
| Avg | 0.95 | -3.22 | -3.23 | ||
| Low | 0.71 | -3.67 | -4.41 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.